Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Investment Securities (2019 - 2025)

Biodesix (BDSX) has disclosed Gains from Investment Securities for 7 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 95.41% year-over-year to $29000.0, compared with a TTM value of $29000.0 through Dec 2025, down 95.57%, and an annual FY2025 reading of $29000.0, down 86.06% over the prior year.
  • Gains from Investment Securities was $29000.0 for Q4 2025 at Biodesix, down from $1.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.0 million in Q2 2024 and bottomed at -$3.6 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $716970.8, with a median of $336500.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 5535.29% in 2021, while the deepest fall reached 339.22% in 2021.
  • Year by year, Gains from Investment Securities stood at $163000.0 in 2021, then plummeted by 2290.8% to -$3.6 million in 2022, then soared by 60.99% to -$1.4 million in 2023, then surged by 145.37% to $632000.0 in 2024, then plummeted by 95.41% to $29000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for BDSX at $29000.0 in Q4 2025, $1.8 million in Q2 2025, and $45000.0 in Q1 2025.